Endostatin binds biglycan and LDL and interferes with LDL retention to the subendothelial matrix during atherosclerosis
Open Access
- 1 September 2005
- journal article
- Published by Elsevier in Journal of Lipid Research
- Vol. 46 (9) , 1849-1859
- https://doi.org/10.1194/jlr.m500241-jlr200
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Loss of Collagen XVIII Enhances Neovascularization and Vascular Permeability in AtherosclerosisCirculation, 2004
- Actin Polymerization in Macrophages in Response to Oxidized LDL and Apoptotic Cells: Role of 12/15-Lipoxygenase and Phosphoinositide 3-KinaseMolecular Biology of the Cell, 2003
- Minimally Modified LDL Binds to CD14, Induces Macrophage Spreading via TLR4/MD-2, and Inhibits Phagocytosis of Apoptotic CellsJournal of Biological Chemistry, 2003
- Laminin Modulates Morphogenic Properties of the Collagen XVIII Endostatin DomainPublished by Elsevier ,2002
- Assessment of Antiangiogenic Effect Using99mTc-EC-EndostatinCancer Biotherapy & Radiopharmaceuticals, 2002
- Accumulation of Biglycan and Perlecan, but Not Versican, in Lesions of Murine Models of AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2002
- Biglycan, a Vascular Proteoglycan, Binds Differently to HDL 2 and HDL 3Arteriosclerosis, Thrombosis, and Vascular Biology, 2001
- Endostatins derived from collagens XV and XVIII differ in structural and binding properties, tissue distribution and anti-angiogenic activityJournal of Molecular Biology, 2000
- Crystal structure of the angiogenesis inhibitor endostatin at 1.5AresolutionThe EMBO Journal, 1998
- Effect of arterial proteoglycans on the interaction of LDL with human monocyte-derived macrophagesAtherosclerosis, 1987